Search Results | MSF Science Portal

Journal Article

|

Commentary

Guglielmetti L, Panda S, Abubakirov A, Salahuddin N, Perrin C, et al.

2025-03-21 • Lancet Respiratory Medicine

Journal Article

|

Editorial

Kuksa L, Andrejak C, Haecker B, Bothamley G, Calcagno A, et al.

2025-03-01 • IJTLD OPEN

Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approve...

Journal Article

|

Research

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, et al.

2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

Conference Material

|

Slide Presentation

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N, et al.

2024-05-16 • MSF Scientific Day International 2024

Conference Material

|

Video

Guglielmetti L

2024-05-16 • MSF Scientific Day International 2024

Conference Material

|

Abstract

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N, et al.

2024-05-16 • MSF Scientific Day International 2024

INTRODUCTION
Tuberculosis (TB) is a major public health challenge encountered across many Médecins Sans Frontières (MSF) fields. Management of drug-resistant TB is an operational pri...

Journal Article

|

Letter

Rupasinghe P, Ashraf A, Barreda N, Parveen S, Zubair M, et al.

2024-05-02 • Antimicrobial Agents and Chemotherapy

Journal Article

|

Research

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A, et al.

2024-01-29 • medRxiv

BACKGROUND

Aft...

Journal Article

|

Research

du Cros PAK, Greig J, Cross GB, Cousins C, Berry C, et al.

2023-12-01 • International Journal of Tuberculosis and Lung Disease

BACKGROUND
The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best practice.

METH...

Journal Article

|

Protocol

Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M, et al.

2023-11-30 • Trials

BACKGROUND
Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...

Journal Article

|

Review

Motta I, Boeree M, Chesov D, Dheda K, Günther G, et al.

2023-07-21 • Clinical Microbiology and Infection

BACKGROUND
Tuberculosis is a global health challenge and one of the leading causes of death worldwide. In the last decade, the tuberculosis treatment landscape has dramatically chang...

Journal Article

|

Letter

Campbell JR, Chan ED, Anderson LF, Bonnet M, Brode SK, et al.

2023-04-01 • International Journal of Tuberculosis and Lung Disease

Journal Article

|

Commentary

Varaine FFV, Guglielmetti L, Mitnick CD

2017-07-17 • American Journal of Respiratory and Critical Care Medicine

Journal Article

|

Commentary

Guglielmetti L, Huerga H, Khan UT, Varaine T

2020-03-01 • European Respiratory Journal

Journal Article

|

Letter

Varaine FFV, Guglielmetti L, Huerga H, Bonnet MMB, Kiria N, et al.

2016-10-15 • American Journal of Respiratory and Critical Care Medicine

Journal Article

|

Commentary

Hewison CCH, Guglielmetti L

2021-02-12 • Lancet Infectious Diseases

We are not alone in welcoming the study by Kelly E Dooley and colleagues 1 that sheds light on the QT prolonging effects of the combination of bedaquiline and delamanid, two key drugs fo...

Journal Article

|

Commentary

Cox V, McKenna L, Acquah R, Reuter A, Wasserman S, et al.

2020-11-01 • International Journal of Tuberculosis and Lung Disease

Rapid diagnostics, newer drugs, repurposed medications, and shorter regimens have radically altered the landscape for treating rifampicin-resistant TB (RR-TB) and multidrug-resistant TB ...

Journal Article

|

Research

Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JWC, Anderson LF, et al.

2018-09-08 • Lancet

BACKGROUND
Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, ...

Journal Article

|

Protocol

Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, et al.

2021-09-25 • Trials

BACKGROUND
Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. W...

Journal Article

|

Letter

Bastard M, Guglielmetti L, Huerga H, Hayrapetyan A, Khachatryan N, et al.

2018-07-03 • American Journal of Respiratory and Critical Care Medicine

Science Portal

Equitable, personalised medicine for tuberculosis: Treating patients, not diseases

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Reduced critical concentration might not have improved MGIT-based DST’s sensitivity to rifampicin

Nine-month, all-oral regimens for rifampin-resistant tuberculosis

Standards for clinical trials for treating TB

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Recent advances in the treatment of tuberculosis

Association of smoking and alcohol use with rifampin-resistant TB treatment outcomes

Reply from the Authors of Eligibility for the Shorter MDR-TB Regimen: Ambiguities in the WHO Recommendations

WHO 2019 guidelines on drug-resistant tuberculosis treatment: based on evidence or expert opinion?

Eligibility for the shorter multidrug-resistant tuberculosis regimen: ambiguities in the World Health Organization recommendations

Cardiac safety of multidrug-resistant tuberculosis treatment: moving towards individualised monitoring

Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

Bedaquiline and Repurposed Drugs for Fluoroquinolone-Resistant MDR-TB: How Much Better Are They?